TROP2‐targeted ADCs demonstrate survival benefit for patients with advanced triple‐negative breast cancer

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, TROP2‐targeted antibody–drug conjugates demonstrate a survival benefit for patients with advanced triple‐negative breast cancer. In addition, sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR ‐mutant advanced non–small cell lung cancer, and an immunochemotherapy regimen demonstrates survival benefits for patients with platinum‐resistant ovarian cancer.